Antimyoclonic Action of Piracetam

Authors:
Publisher website
Google Scholar
Abstract
Five patients with myoelonus were treated with oral piracetam (8–9 g/day). All patients had action-sensitive and/or stimulus-sensitive myoclonus and enhanced amplitude of somatosensory evoked potentials. Piracetam produced a marked reduction of the myoclonus in the five subjects without side effects. In view of its excellent tolerance and synergism with other antimyoclonic drugs, we consider piracetam to be a very valuable drug for the treatment of patients with myoelonus of any origin.